0.2848  0.018 (6.87%)		04-25 16:00
Open: 0.27 High: 0.29 Volume: 1,937,000		Pre. Close: 0.2665 Low: 0.25 Market Cap: 7(M)

Short term
Mid term
Targets	6-month :	0.41	1-year :	0.51
Resists	First :	0.35	Second :	0.43
Pivot price	0.26
Supports	First :	0.21	Second :	0.18
MAs	MA(5) :	0.24	MA(20) :	0.27
	MA(100) :	0.57	MA(250) :	1.15
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	21.7	D(3) :	11.7
RSI	RSI(14): 48.3
52-week	High :	4.09	Low :	0.21

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GNPX ] has closed below upper band by 32.0%. Bollinger Bands are 56.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.29 - 0.29	0.29 - 0.29
Low:	0.25 - 0.25	0.25 - 0.25
Close:	0.28 - 0.28	0.28 - 0.29

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Thu, 24 Apr 2025
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting | GNPX Stock News - GuruFocus

Thu, 24 Apr 2025
Breakthrough Gene Therapy Trial Design for Small Cell Lung Cancer Maintenance Treatment Selected for ASCO 2025 - Stock Titan

Tue, 22 Apr 2025
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings | GNPX Stock News - GuruFocus

Tue, 22 Apr 2025
Cancer Research Reveals Breakthrough: Gene Therapy Defeats Drug-Resistant Lung Cancer in Latest Study - Stock Titan

Tue, 22 Apr 2025
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings - Yahoo Finance

Tue, 01 Apr 2025
Genprex Inc. (GNPX) reports earnings - qz.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	9 (M)
Shares Float	8 (M)
Held by Insiders	1.2 (%)
Held by Institutions	3.4 (%)
Shares Short	334 (K)
Shares Short P.Month	1,130 (K)

EPS	-5.35
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.3
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-138.9 %
Return on Equity (ttm)	-325.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.69
Qtrly Earnings Growth	0 %
Operating Cash Flow	-18 (M)
Levered Free Cash Flow	-12 (M)

PE Ratio	-0.06
PEG Ratio	0
Price to Book value	0.94
Price to Sales	0
Price to Cash Flow	-0.14

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.